Hyderabad: In the validation Covaxin role has been playing in the fight against the pandemic Covid-19 duo founder of Bharat Biotech Dr Krishna Ella and his wife Suchitra Ella was awarded the Padma Bhushan on Tuesday.
In the 68 years since the Padma Award instituted, this is a rare instance when the husband-wife duo has been honored with the third highest civilian award in the country.
While Dr Krishna Ella (66) to encourage innovation in Bharat Biotech, Suchitra Ella (57) directs the operational and commercial aspects of the company based in Hyderabad.
Suchitra Ella, as insiders pointed out, referring to himself as the heart and brains behind her husband as Bharat Biotech.
The award is seen as the culmination of a roller-coaster ride that is thrilling but stressed that developing a vaccine Covid first India-19 from the beginning has proved to couples who set up Bharat Biotech in Hyderabad in 1996.
In fact, Krishna Ella had told TOI in an exclusive interview recently that many hair twists and spins on the way Covaxin snatched from a good 10 years of his life in just 18 months.
“The last 18 months was a tough time.
The way I fought.
I have not fought basking in the last 25 years (since he founded the Bharat Biotech),” said Ella Toi, referring to the intense scrutiny, the couple will ever before Since the company started developing Covaxin April 2020.
Less than two years after Bharat Biotech began to develop Covaxin, more than 22.75 crore doses have been given to those aged 15 years and above in India, not to forget the millions of doses exports to over 25 countries.
.
Covaxin also the 19th Covid first vaccine to be tested in children as young as 2 years, but so far approved only for the 15-18 year age bracket.
This also applies to the Indian drug regulator for a full commercial license.
Covaxin success story also marks the emergence of India as a serious player to be reckoned with in the global innovation landscape.
Ellas, who quit Cushy jobs in the US and decided to return to India in 1995-95 to pursue their entrepreneurial dreams with their two children JACHARI (12) and Raches (6), no longer just satisfied with the success that is not active.
Covaxin whole virus vaccine.
Their company is also experiencing the intra-nasal vaccine – BBV154 – that he hopes will play a role in the 19th Covid bid adieu if proved successful in preventing the transmission of SARS-CoV-2 as some other nasal vaccine candidates out of the race.
With more than 160 patents, Bharat Biotech has more than 16 vaccines in its portfolio and employs more than 2,600 people.
Regardless of Covaxin, the company has developed and successfully launched rotovac vaccines such as rotavirus vaccine, typhoid conjugate vaccine TCV Typbar, even as it is working on a vaccine for Zika virus and Chikungunya.